US9084842B1 - Dermal filler composition - Google Patents

Dermal filler composition Download PDF

Info

Publication number
US9084842B1
US9084842B1 US13/888,651 US201313888651A US9084842B1 US 9084842 B1 US9084842 B1 US 9084842B1 US 201313888651 A US201313888651 A US 201313888651A US 9084842 B1 US9084842 B1 US 9084842B1
Authority
US
United States
Prior art keywords
filler composition
injectable filler
injectable
weight percent
white colorant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US13/888,651
Inventor
Rania Agha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/888,651 priority Critical patent/US9084842B1/en
Priority to US14/803,512 priority patent/US9981065B2/en
Application granted granted Critical
Publication of US9084842B1 publication Critical patent/US9084842B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/442—Colorants, dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • Injectable dermal fillers are widely used by dermatologists and plastic surgeons to soften deep folds and reduce wrinkles on the faces of patients, such as lines from the nose to the corners of the mouth and “crows feet” which extend from the corners of the mouth. They are also commonly used as a lip augmentation agent and to fill in hollow places and scars on the face.
  • the injectable dermal fillers used in such applications are typically comprised of hyaluronic acid because it can absorb up to 1000 times its own weight in water which accordingly adds volume under the surface of sagging skin to provide a more youthful appearance.
  • Hyaluronic acid is also believed to bind to collagen present in the skin to enhance firming. There is some evidence that hyaluronic acid stimulates additional collagen formation which is highly advantageous since collagen supports the skin structure.
  • Dermal fillers can also be injected into the skin of the orbital trough of a patient to firm the skin in the area around the eyes.
  • this procedure is complicated by the fact that some people develop dark circles around their eyes with age.
  • the injection of dermal fillers aggravates this problem and can cause such dark areas to have an even darker appearance due to the Tyndall effect. This is caused by the filler particles scattering the light in a manner that results in a darker appearance (black or dark blue). Accordingly, the use of dermal fillers in the orbital trough of patients that have developed dark circles around their eyes can be problematic.
  • the present invention is relates to an injectable dermal filler composition that can be injected into the skin of the orbital trough of a patient without aggravating darkness around the eyes of the patient. In fact, this composition can be used to lighten such dark areas which have developed over time.
  • the present invention more specifically discloses an injectable dermal filler composition comprising hyaluronic acid and a white colorant.
  • the present invention further reveals a method for treating wrinkles and firming an area of skin on a human patient comprising injecting an injectable dermal filler composition comprising hyaluronic acid and a white colorant, into an area of skin on the human patient.
  • the injectable dermal filler composition of this invention is comprised of hyaluronic acid and a white colorant.
  • the hyaluronic acid will typically be crosslinked and will normally be in the form of a gel.
  • Hyaluronic acid which is suitable for use in the practice of this invention is commercially available as JuvedermTM, RestylaneTM, and PerlaneTM
  • the white colorant will preferably be non-toxic.
  • Some representative examples of white colorants that can be used include: lead carbonate, titanium dioxide, barium sulfate, zinc oxide, calcium carbonate, calcium oxide, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, and calcium phosphate.
  • the white colorant will preferably be a calcium compound, such as calcium carbonate, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, or calcium phosphate.
  • the white colorant will typically be present in the injectable dermal filler composition of this invention at a level which is within the range of about 1 weight percent to about 40 weight percent, based upon the total weight of the injectable filler composition.
  • the white colorant will more typically be present in the injectable filler composition at a level which is within the range of about 2 weight percent to about 35 weight percent, based upon the total weight of the injectable filler composition.
  • the white colorant can be present in the injectable filler composition at a level which is within the range of about 5 weight percent to about 30 weight percent, based upon the total weight of the injectable filler composition.
  • the white colorant can also be present in the injectable filler composition at a level which is within the range of about 10 weight percent to about 25 weight percent, based upon the total weight of the injectable filler composition. In another scenario, the white colorant can be present in the injectable filler composition at a level which is within the range of about 10 weight percent to about 20 weight percent, based upon the total weight of the injectable filler composition.
  • the injectable dermal filler composition of this invention can optionally further include a yellow colorant.
  • yellow colorant that can be used include: cadmium yellow, ochres, curcuma yellow, chrome yellow, and disazodiarylide. It is normally preferred for the injectable dermal filler composition of this invention to also contain lidocaine.
  • the injectable dermal filler composition of this invention is injected into an area of skin on the human patient. This area will typically be within the orbital trough of the patient, such as the area under the eyes of the patient.
  • the amount of the injectable dermal filler composition injected will typically be within the range of about 0.25 ml to about 2 ml.
  • the amount of the injectable dermal filler composition injected will more typically be within the range of about 0.25 ml to about 1.5 ml.
  • the amount of the injectable dermal filler composition injected can be within the range of about 0.5 ml to about 1.5 ml.
  • the amount of the injectable dermal filler composition injected can also be within the range of about 0.5 ml to about 1.25 ml or it can be within the range of about 0.75 ml to about 1.25 ml. In many cases the amount of dermal filler composition injected will be within the range of about 0.75 ml to about 1 ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)

Abstract

The present invention relates to an injectable dermal filler composition that can be injected into the skin of the orbital trough of a patient without aggravating darkness around the eyes of the patient. In fact, this composition can be used to lighten such dark areas which have developed over time. The present invention more specifically discloses an injectable dermal filler composition comprising hyaluronic acid and a white colorant. The present invention further reveals a method for treating wrinkles and firming an area of skin on a human patient comprising injecting an injectable dermal filler composition comprising hyaluronic acid and a white colorant, into the area of skin on the human patient.

Description

This application claims benefit of U.S. Provisional Patent Application Ser. No. 61/643,600, filed on May 7, 2012. The teachings of U.S. Provisional Patent Application Ser. No. 61/643,600 are incorporated herein by reference in their entirety.
BACKGROUND OF THE INVENTION
Injectable dermal fillers are widely used by dermatologists and plastic surgeons to soften deep folds and reduce wrinkles on the faces of patients, such as lines from the nose to the corners of the mouth and “crows feet” which extend from the corners of the mouth. They are also commonly used as a lip augmentation agent and to fill in hollow places and scars on the face.
The injectable dermal fillers used in such applications are typically comprised of hyaluronic acid because it can absorb up to 1000 times its own weight in water which accordingly adds volume under the surface of sagging skin to provide a more youthful appearance. Hyaluronic acid is also believed to bind to collagen present in the skin to enhance firming. There is some evidence that hyaluronic acid stimulates additional collagen formation which is highly advantageous since collagen supports the skin structure.
Dermal fillers can also be injected into the skin of the orbital trough of a patient to firm the skin in the area around the eyes. However, this procedure is complicated by the fact that some people develop dark circles around their eyes with age. The injection of dermal fillers aggravates this problem and can cause such dark areas to have an even darker appearance due to the Tyndall effect. This is caused by the filler particles scattering the light in a manner that results in a darker appearance (black or dark blue). Accordingly, the use of dermal fillers in the orbital trough of patients that have developed dark circles around their eyes can be problematic.
SUMMARY OF THE INVENTION
The present invention is relates to an injectable dermal filler composition that can be injected into the skin of the orbital trough of a patient without aggravating darkness around the eyes of the patient. In fact, this composition can be used to lighten such dark areas which have developed over time. The present invention more specifically discloses an injectable dermal filler composition comprising hyaluronic acid and a white colorant.
The present invention further reveals a method for treating wrinkles and firming an area of skin on a human patient comprising injecting an injectable dermal filler composition comprising hyaluronic acid and a white colorant, into an area of skin on the human patient.
DETAILED DESCRIPTION OF THE INVENTION
The injectable dermal filler composition of this invention is comprised of hyaluronic acid and a white colorant. The hyaluronic acid will typically be crosslinked and will normally be in the form of a gel. Hyaluronic acid which is suitable for use in the practice of this invention is commercially available as Juvederm™, Restylane™, and Perlane™
The white colorant will preferably be non-toxic. Some representative examples of white colorants that can be used include: lead carbonate, titanium dioxide, barium sulfate, zinc oxide, calcium carbonate, calcium oxide, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, and calcium phosphate. The white colorant will preferably be a calcium compound, such as calcium carbonate, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, or calcium phosphate.
The white colorant will typically be present in the injectable dermal filler composition of this invention at a level which is within the range of about 1 weight percent to about 40 weight percent, based upon the total weight of the injectable filler composition. The white colorant will more typically be present in the injectable filler composition at a level which is within the range of about 2 weight percent to about 35 weight percent, based upon the total weight of the injectable filler composition. For instance the white colorant can be present in the injectable filler composition at a level which is within the range of about 5 weight percent to about 30 weight percent, based upon the total weight of the injectable filler composition. The white colorant can also be present in the injectable filler composition at a level which is within the range of about 10 weight percent to about 25 weight percent, based upon the total weight of the injectable filler composition. In another scenario, the white colorant can be present in the injectable filler composition at a level which is within the range of about 10 weight percent to about 20 weight percent, based upon the total weight of the injectable filler composition.
The injectable dermal filler composition of this invention can optionally further include a yellow colorant. Some representative examples of yellow colorant that can be used include: cadmium yellow, ochres, curcuma yellow, chrome yellow, and disazodiarylide. It is normally preferred for the injectable dermal filler composition of this invention to also contain lidocaine.
In accordance with this invention, the injectable dermal filler composition of this invention is injected into an area of skin on the human patient. This area will typically be within the orbital trough of the patient, such as the area under the eyes of the patient. The amount of the injectable dermal filler composition injected will typically be within the range of about 0.25 ml to about 2 ml. The amount of the injectable dermal filler composition injected will more typically be within the range of about 0.25 ml to about 1.5 ml. For instance, the amount of the injectable dermal filler composition injected can be within the range of about 0.5 ml to about 1.5 ml. The amount of the injectable dermal filler composition injected can also be within the range of about 0.5 ml to about 1.25 ml or it can be within the range of about 0.75 ml to about 1.25 ml. In many cases the amount of dermal filler composition injected will be within the range of about 0.75 ml to about 1 ml.

Claims (10)

What is claimed is:
1. An injectable dermal filler composition comprising hyaluronic acid, wherein the hyaluronic acid is crosslinked, a white colorant, and a yellow colorant selected from the group consisting of cadmium yellow, ochres, and chrome yellow.
2. The injectable filler composition as specified in claim 1 wherein the hyaluronic acid is in the form of a gel.
3. The injectable filler composition as specified in claim 1 wherein the white colorant is non-toxic.
4. The injectable filler composition as specified in claim 1 wherein the white colorant is selected from the group consisting of lead carbonate, titanium dioxide, barium sulfate, zinc oxide, calcium carbonate, calcium oxide, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, and calcium phosphate.
5. The injectable filler composition as specified in claim 1 wherein the white colorant is present in the injectable filler composition at a level which is within the range of about 1 weight percent to about 40 weight percent, based upon the total weight of the injectable filler composition.
6. The injectable filler composition as specified in claim 1 wherein the white colorant is present in the injectable filler composition at a level which is within the range of about 2 weight percent to about 35 weight percent, based upon the total weight of the injectable filler composition.
7. The injectable filler composition as specified in claim 1 wherein the white colorant is present in the injectable filler composition at a level which is within the range of about 5 weight percent to about 30 weight percent, based upon the total weight of the injectable filler composition.
8. The injectable filler composition as specified in claim 1 wherein the white colorant is present in the injectable filler composition at a level which is within the range of about 10 weight percent to about 25 weight percent, based upon the total weight of the injectable filler composition.
9. The injectable filler composition as specified in claim 1 wherein the white colorant is present in the injectable filler composition at a level which is within the range of about 10 weight percent to about 20 weight percent, based upon the total weight of the injectable filler composition.
10. The injectable filler composition as specified in claim 1 wherein the injectable filler composition is further comprised of lidocaine.
US13/888,651 2012-05-07 2013-05-07 Dermal filler composition Expired - Fee Related US9084842B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/888,651 US9084842B1 (en) 2012-05-07 2013-05-07 Dermal filler composition
US14/803,512 US9981065B2 (en) 2012-05-07 2015-07-20 Dermal filler composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643600P 2012-05-07 2012-05-07
US13/888,651 US9084842B1 (en) 2012-05-07 2013-05-07 Dermal filler composition

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/803,512 Division US9981065B2 (en) 2012-05-07 2015-07-20 Dermal filler composition
US14/803,512 Continuation-In-Part US9981065B2 (en) 2012-05-07 2015-07-20 Dermal filler composition

Publications (1)

Publication Number Publication Date
US9084842B1 true US9084842B1 (en) 2015-07-21

Family

ID=53540043

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/888,651 Expired - Fee Related US9084842B1 (en) 2012-05-07 2013-05-07 Dermal filler composition
US14/803,512 Expired - Fee Related US9981065B2 (en) 2012-05-07 2015-07-20 Dermal filler composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/803,512 Expired - Fee Related US9981065B2 (en) 2012-05-07 2015-07-20 Dermal filler composition

Country Status (1)

Country Link
US (2) US9084842B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017127902A1 (en) * 2017-11-27 2019-05-29 Sensient Colors Europe Gmbh Composition for coloring food
DE102020003477A1 (en) 2020-06-10 2021-12-16 DÖHLER GmbH Pigment for the whitening of food, dietary supplements, cosmetic or pharmaceutical products

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105769603A (en) * 2016-03-02 2016-07-20 陈思敏 Micro-injection powder foundation and preparation method thereof
KR102833738B1 (en) * 2023-03-22 2025-07-14 한준 Composition for fat under eyes and special make-up method using thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202625A1 (en) * 2003-04-10 2004-10-14 Daniloff George Y. Compositions and methods of using a transient colorant
FR2919999A1 (en) * 2007-08-13 2009-02-20 Oreal Cosmetic/pharmaceutical composition, useful to treat e.g. loss of dermal/epidermal volume, for filling depressions on skin surface and to treat wrinkles, and/or restore facial fullness, comprises hyaluronic acid and divalent cation
US20100100179A1 (en) * 1992-02-11 2010-04-22 Bioform Medical, Inc. Tissue Augmentation Material and Method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2681197T3 (en) * 2007-12-14 2018-09-12 Basf Se Sunscreen compositions containing color pigments
US20130096081A1 (en) * 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100100179A1 (en) * 1992-02-11 2010-04-22 Bioform Medical, Inc. Tissue Augmentation Material and Method
US20040202625A1 (en) * 2003-04-10 2004-10-14 Daniloff George Y. Compositions and methods of using a transient colorant
FR2919999A1 (en) * 2007-08-13 2009-02-20 Oreal Cosmetic/pharmaceutical composition, useful to treat e.g. loss of dermal/epidermal volume, for filling depressions on skin surface and to treat wrinkles, and/or restore facial fullness, comprises hyaluronic acid and divalent cation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Machine translation of FR 2919999 (2007). *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017127902A1 (en) * 2017-11-27 2019-05-29 Sensient Colors Europe Gmbh Composition for coloring food
DE102020003477A1 (en) 2020-06-10 2021-12-16 DÖHLER GmbH Pigment for the whitening of food, dietary supplements, cosmetic or pharmaceutical products

Also Published As

Publication number Publication date
US20150320907A1 (en) 2015-11-12
US9981065B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
US9981065B2 (en) Dermal filler composition
US8455459B2 (en) Method of applying an injectable filler
CN104042545B (en) A kind ofly subtract skin-protection product in age for cytogene Regeneration and Repair
KR101735384B1 (en) Clay hydrogel composition for sheet type pack and sheet type clay hydrogel mask pack using the same
Coleman et al. Cross-linked hyaluronic acid fillers
CN106215244A (en) The compound recipe solution of hyaluronate sodium and the application of correction wrinkle of skin thereof
Bray et al. Injection rhinoplasty: non-surgical nasal augmentation and correction of post-rhinoplasty contour asymmetries with hyaluronic acid: how we do it
Haik et al. Reconstruction of full-thickness defects with bovine-derived collagen/elastin matrix: a series of challenging cases and the first reported post-burn facial reconstruction
KR20190002810A (en) Water Dispersion Liquid Cosmetic Composition for Eye-makeup
Vleggaar Poly‐L‐lactic acid: consultation on the injection techniques
Md Injection techniques for revolumization of the perioral region with hyaluronic acid
Arsiwala Safety and persistence of non-animal stabilized hyaluronic acid fillers for nasolabial folds correction in 30 Indian patients
Viana Treatment of tear trough deformity with hyaluronic acid gel filler
CN106109279A (en) A kind of Flos Rosae Rugosae collagen protein peptide facial mask
Solish Assessment of recovery time for the collagen products Dermicol-P35 27G and 30G
Alghonaim et al. Bilateral lower-lip foreign body granuloma secondary to hyaluronic acid injection
Suominen et al. Free latissimus dorsi perforator flap for reconstruction of hemifacial atrophy: case report
Kovach Table of Fillers
Ting Face Facts
Lee Prominent Nasolabial Fold: An Overview of Treatments.
WOLLINA et al. THE POTENTIAL RISK OF LIP OVERFILLING FOR DERMAL ELASTIC FIBER NETWORK.
CN107510643A (en) A kind of naked adornment for adding Nano pearl powder repaiies face frost and preparation method in vain thoroughly
KR20240143764A (en) Composition for fat under eyes and Treatment method using thereof
Zyderm et al. Lip augmentation
Kaladze DERMAL FILLERS FOR FACIAL ENHANCEMENT

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20190721